Brokerages forecast that Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) will post earnings per share of ($0.14) for the current quarter, according to Zacks. Zero analysts have issued estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.15). Aptose Biosciences posted earnings per share of ($0.30) during the same quarter last year, which indicates a positive year over year growth rate of 53.3%. The company is expected to report its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.70) to ($0.54). For the next fiscal year, analysts expect that the firm will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.80) to ($0.64). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that follow Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03.

A number of research firms recently weighed in on APTO. Roth Capital reiterated a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, May 23rd. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Friday, March 15th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Royal Bank of Canada began coverage on Aptose Biosciences in a research report on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.75.

In related news, Director Erich Platzer sold 20,000 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased a total of 27,500 shares of company stock valued at $51,300 in the last quarter. 7.34% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Aptose Biosciences in the first quarter worth $35,000. Patriot Financial Group Insurance Agency LLC increased its position in Aptose Biosciences by 37.3% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock worth $158,000 after buying an additional 21,400 shares during the period. Boston Advisors LLC acquired a new stake in Aptose Biosciences in the first quarter worth $36,000. Virtu Financial LLC acquired a new stake in Aptose Biosciences in the first quarter worth $198,000. Finally, Geode Capital Management LLC acquired a new stake in Aptose Biosciences in the fourth quarter worth $33,000. Institutional investors and hedge funds own 7.53% of the company’s stock.

Shares of NASDAQ:APTO traded up $0.14 during midday trading on Wednesday, reaching $2.15. The company had a trading volume of 654,522 shares, compared to its average volume of 290,342. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.09. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $4.55. The firm has a market capitalization of $87.09 million, a price-to-earnings ratio of -2.50 and a beta of 1.43.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Story: What is systematic risk?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.